Last reviewed · How we verify
bupivacaine 0.25% And verapamil — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
bupivacaine 0.25% And verapamil (bupivacaine 0.25% And verapamil) — Ain Shams University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| bupivacaine 0.25% And verapamil TARGET | bupivacaine 0.25% And verapamil | Ain Shams University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- bupivacaine 0.25% And verapamil CI watch — RSS
- bupivacaine 0.25% And verapamil CI watch — Atom
- bupivacaine 0.25% And verapamil CI watch — JSON
- bupivacaine 0.25% And verapamil alone — RSS
Cite this brief
Drug Landscape (2026). bupivacaine 0.25% And verapamil — Competitive Intelligence Brief. https://druglandscape.com/ci/bupivacaine-0-25-and-verapamil. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab